HeartMate 3 in Lowest INTERMACS Profile Cohort: The Swiss Experience.

Détails

ID Serval
serval:BIB_530D8CB90758
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
HeartMate 3 in Lowest INTERMACS Profile Cohort: The Swiss Experience.
Périodique
ASAIO journal
Auteur(s)
Tozzi P., Banfi C., Ahmadov K., Hullin R., Meyer P., Giraud R., Liaudet L., Gronchi F., Huber C., Kirsch M.
ISSN
1538-943X (Electronic)
ISSN-L
1058-2916
Statut éditorial
Publié
Date de publication
2017
Peer-reviewed
Oui
Volume
63
Numéro
6
Pages
752-758
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
New generation devices for long-term mechanical circulatory support are centrifugal pumps having fully magnetically levitated rotors to reduce blood trauma. Recently, the novel HeartMate 3 was cleared for clinical application in Switzerland. In two Swiss University Hospitals part of the "Lausanne-Geneva Transplantation Network," 10 consecutive patients in end-stage heart failure received the HeartMate 3 (Thoratec Corporation, Pleasanton, CA). Device implantation criteria were persistent low output syndrome despite optimal medical treatment. The primary end-point of the study was survival or transplantation to 90 days on the device. Five patients (50%) were in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) class 1 and 2 (two were under venoarterial extracorporeal membrane oxygenation [VA-ECMO]), and five were in class 3 and 4. The indication was bridge-to-transplant in seven patients, and destination therapy in three. Two patients (20%) received concomitant aortic valve surgery. Four patients (40%) required temporary right ventricle support (tRVAD) for a mean of 8 ± 1.5 days. Bleeding requiring surgical revision occurred in five (50%) patients, two during the tRVAD support. At the 90 day end-point, survival was 90%, one (10%) died due to respiratory failure. Three (30%) experienced critical illness polyneuropathy. Two had body temperature over 38.5°C for more than 7 days after implant, without infections. Two (20%) had late driveline infection. The pump allowed rapid improvement of patients' clinical conditions even in severely compromised patients. Postoperative bleeding occurred in the setting of anticoagulation. No hemolysis or pump thrombosis occurred. Fever occurred frequently but was not associated with mortality. Hemodynamic support was consistent over time without significant adverse events.
Mots-clé
Adult, Aged, Female, Heart Failure/mortality, Heart Failure/therapy, Heart Transplantation, Heart-Assist Devices/adverse effects, Humans, Male, Middle Aged, Prospective Studies, Registries
Pubmed
Web of science
Création de la notice
06/06/2017 19:02
Dernière modification de la notice
20/08/2019 15:08
Données d'usage